J Biol Chem, Vol. 274, Issue 34, 23948-23955, August 20, 1999
Cytosine Methylation in a CpG Sequence Leads to Enhanced
Reactivity with Benzo[a]pyrene Diol Epoxide That
Correlates with a Conformational Change*
Daniel J.
Weisenberger and
Louis J.
Romano
From the Department of Chemistry, Wayne State University,
Detroit, Michigan 48202
 |
ABSTRACT |
Benzo[a]pyrene
(B[a]P) is a widespread environmental carcinogen that
must be activated by cellular metabolism to a diol epoxide form (BPDE)
before it reacts with DNA. It has recently been shown that BPDE
preferentially modifies the guanine in methylated 5'-CpG-3' sequences
in the human p53 gene, providing one explanation for why these sites
are mutational hot spots. Using purified duplex oligonucleotides
containing identical methylated and unmethylated CpG sequences, we show
here that BPDE preferentially modified the guanine in hemimethylated or
fully methylated CpG sequences, producing between 3- and 8-fold more
modification at this site. Analysis of this reaction using shorter
duplex oligonucleotides indicated that it was the level of the
(+)-trans isomer that was specifically increased. To
determine if there were conformational differences between the
methylated and unmethylated B[a]P-modified DNA sequences
that may be responsible for this enhanced reactivity, a native
polyacrylamide gel electrophoresis analysis was carried out using DNA
containing isomerically pure B[a]P-DNA adducts. These
experiments showed that each adduct resulted in an altered gel mobility
in duplex DNA but that only the presence of a (+)-trans isomer and a methylated C 5' to the adduct resulted in a significant gel mobility shift compared with the unmethylated case.
 |
INTRODUCTION |
Benzo[a]pyrene
(B[a]P)1 is a
well studied polycyclic aromatic hydrocarbon (for reviews see Refs. 1
and 2) that is ultimately converted by the P450 mixed oxygenase system
(1, 3) to one of four diasteromeric diol epoxides:
(+)-anti-BPDE, (
)-anti-BPDE, (+)-syn-BPDE, and (
)-syn-BPDE (4, 5). The
(±)-anti-BPDE forms are thought to be the most biologically
relevant (6), and these enantiomers display very different
mutagenicities depending on the host system: the (
)-anti
form is more mutagenic in bacteria, (7) whereas
(+)-anti-BPDE is more mutagenic in mammalian cells (7, 8)
and is widely considered to be the ultimate carcinogenic form of BPDE
(9).
Regardless of the stereochemistry of anti-BPDE, it is highly
reactive, and the major adducts are formed by the cis or
trans opening of the epoxide at the C-10 position by the
exocyclic amine of guanine (10). The four major guanine adducts are
shown in Fig. 1A (11). BPDE also reacts to a lesser extent
with the N-6 position of adenine (11) residues to form similar
enantiomeric mixtures.
The (+)-trans-anti-B[a]P-dGuo adduct
is the major form produced following either in vivo or
in vitro treatment, and NMR solution studies have shown that
this adduct resides in the minor groove of DNA pointing toward the
5'-end of the adducted DNA strand (12). The (
)-trans
adduct is also positioned in the minor groove but points in the 3'
direction (13). Phosphodiesterase digestion of single-stranded DNA
oligomers containing the trans adducts have also shown these
same adduct orientations (14). NMR studies indicate that both of the
cis isomers are more intercalated into the helix, with the
(+)-cis pointing toward the minor groove and the
(
)-cis isomers pointing toward the major groove (15,
16).
Studies involving isomerically pure B[a]P-DNA adducts have
shown that their presence in duplex or single-stranded DNA can result
in DNA bending that is dependent on the stereochemistry of the adduct
and on the sequence context (17-20). Polyacrylamide gel
electrophoresis (PAGE) studies have shown that B[a]P-DNA
adducts migrate with anomalously slow rates (21), with the
(+)-trans adduct the most retarding, and have suggested that
this adduct induces significant DNA bending (17-19). Other studies
have concluded that the sequence context on the 5'- and 3'-side of the
damaged guanine is also a factor in determining the extent of bending (18, 20).
Recently, it has been shown that the reactivity of BPDE is influenced
by the methylation status of CpG sequences in the p53 gene
(22, 23). It is well established that this gene is mutated in nearly
one-half of all cancers (24) and contains six codons that are major
mutagenic hot spots. Five out of these six are in methylated CpG
sequences (25), and when the DNA binding sites for BPDE were measured
in the p53 sequence in human lung cells (26) or in plasmid DNA (22) it
was found that binding was not only targeted to these same sequences
but also that methylation of the 5'-C was required for the enhanced
reactivity (22). In vitro studies have also shown that
numerous carcinogens, including BPDE and
N-acetoxy-N-acetyl-2-aminofluorene, show enhanced
(2-5-fold) reactivity toward purified p53 DNA when the CpG sequences
are methylated (23).
In the present study, we have used a purified system composed of BPDE
and methylated and unmethylated duplex oligonucleotides to study the
effect of methylation on the reactivity of BPDE at CpG sequences. In
addition, the effect of methylation on B[a]P structure in
DNA was also studied using a PAGE analysis. It was found that the
specific presence of both a 5-mC and a
(+)-trans-B[a]P-dGuo adduct (the major adduct
formed in vivo) resulted in a substantial change in the DNA
structure and that the level of this adduct was specifically
increased when the CpG was methylated.
 |
EXPERIMENTAL PROCEDURES |
Materials--
All DNA oligomers were purchased from Midland
Certified Reagent Co. (Midland, TX). Racemic (±)-anti BPDE
was purchased from the National Cancer Institute Chemical Reference
Standard Repository (Kansas City, MO). T4 polynucleotide kinase and
[
-32P]dideoxy-ATP were purchased from Amersham
Pharmacia Biotech, and terminal deoxynucleotidyl transferase and
DraI enzymes were obtained from Promega.
[
-32P]ATP was purchased from ICN Radiochemicals. All
other general reagents and chemicals were obtained from Fisher and VWR.
BPDE Modification Reactions--
The BPDE modification reactions
used to determine preferential binding involved the 51-mer oligomer
shown in Fig. 1B (top strand). 100 pmol of the 51-mer (containing either a methylated or unmethylated CpG
site) was 5'-end-labeled with T4 polynucleotide kinase and
[
-32P]ATP (7,000 Ci/mmol). In a separate reaction, the
oligonucleotide was 3'-end-labeled with terminal deoxynucleotidyl
transferase and [
-32P]dideoxy-ATP (5,000 Ci/mmol).
These radiolabeled molecules were purified by denaturing polyacrylamide
gel electrophoresis, and approximately 60 pmol were hybridized to a
stoichiometric equivalent of the gel-purified complementary oligomer
containing either a methylated or unmethylated CpG (Fig. 1B,
bottom strand). The annealing reactions (50 µl)
contained 20 mM Tris-HCl, pH 7.5, 10 mM
MgCl2, 50 mM NaCl, 1 mM
dithiothreitol. The reaction mixtures were incubated at 80 °C for 5 min and then slow cooled to room temperature over 60 min. 3-pmol
aliquots of each labeled duplex DNA were incubated with 0-750
µM racemic (±)-anti-BPDE (6 mM
stock dissolved in 19:1 tetrahydrofuran/triethylamine) in a 20-µl
volume for 48 h in the dark at room temperature. The DNA was then
incubated with 5 units of DraI restriction enzyme at
37 °C for 60 min in 6 mM Tris-HCl, pH 7.5, 6 mM MgCl2, 50 mM NaCl, and 1 mM dithiothreitol. Each reaction was heat-inactivated at
80 °C for 5 min, and then an aliquot was added to formamide loading
buffer and electrophoresed on a 15% sequencing gel (containing 8 M urea). The gels were fixed with 10% acetic acid and 30%
methanol and were dried in a Bio-Rad model 483 slab drier. The gels
were analyzed, and the results were quantitated using a Molecular
Dynamics PhosphorImager. The presence of a 3'-labeled 28-mer band
represents the methylated unmodified DNA substrate, and the 5'-labeled
24-mer represents the unmethylated unmodified DNA molecule. The bands
migrating slower than these unmodified bands correspond to the
B[a]P-modified oligonucleotides and were identified by
comparing the gel mobilities with that of B[a]P-modified
oligonucleotide standards. The relative percentages of modification at
each site were measured as a function of the concentration of BPDE in
the reaction relative to the total number of guanines present.
N-Acetoxy-N-acetyl-2-aminofluorene (N-AAAF) Modification
Reactions--
The reaction of N-AAAF with the 51-mer shown
in Fig. 1B was carried out as described for BPDE except as noted.
The radiolabeled 51-mer was purified by denaturing polyacrylamide gel
electrophoresis, and approximately 60 pmol were hybridized to a
stoichiometric equivalent of the gel-purified complementary oligomer
containing a methylated CpG (Fig. 1B, bottom
strand) in 4 mM sodium ascorbate, pH 7.0, in a
60-µl total volume. The annealing mixtures were incubated at 80 °C
for 5 min and then slow cooled to room temperature over 60 min. 3-pmol
aliquots of each labeled duplex DNA were incubated with 0-1.2
mM N-AAAF in a 30-µl reaction volume
containing final concentrations of 2 mM sodium ascorbate,
pH 7.0, and 20% ethanol. The reaction was allowed to proceed for
16 h in the dark at room temperature, after which time a small
aliquot was removed, the DNA was reacted with 5 units of
DraI, and the PAGE analysis was carried out as described for the BPDE reaction. The AAF-modified species migrate slightly slower than the unmodified oligonucleotides and were identified by comparing the gel mobilities with that of AAF-modified and HPLC-purified standards. The relative percentages of AAF modification at each site
were measured as a function of the concentration of N-AAAF in the reaction relative to the total number of guanines present.
Synthesis and Purification of B[a]P-modified
Oligonucleotides--
16-mer sequences (Figs. 4-7) were purified by
HPLC using a Varian 5000 HPLC with a Polychrom 9060 diode array
detector on a Hypersil-ODS column (250 × 4.6 mm) in 20 mM NaPO4, pH 7.0, using a gradient to 45%
methanol at a flow rate of 1 ml/min. Each sample was then desalted
using a Sep-Pak C-18 column. Approximately 40-50 OD units of purified
DNA in 20 mM sodium phosphate, pH 7.0, in a 200-µl total
volume were added to 100 µl of BPDE stock solution. The reactions
were vortexed periodically over the 48-72-h incubation period at room
temperature in the dark. The oligonucleotide products containing each
of the four B[a]P adduct isomers were purified using the
Hypersil-ODS column using the conditions previously described. Each
oligonucleotide was then purified by denaturing 20% PAGE and then
HPLC-purified as described above.
PAGE Analysis of B[a]P-DNA Adducts--
The modified 16-mers
(approximately 10 pmol) were 5'-end-labeled with T4 polynucleotide
kinase and [
-32P]ATP. These single-stranded molecules
were analyzed by 20% denaturing (containing 8 M urea) or
nondenaturing gels. The 16-mer duplexes were formed by removing a small
aliquot (1-2 pmol) from the heat-inactivated labeling reaction and
incubating with a 5-10-fold excess of complement in annealing buffer
(20 mM Tris-HCl, pH 7.5, 50 mM NaCl, 20 mM MgCl2, and 1 mM dithiothreitol)
for 5 min at 80 °C. The samples were cooled to room temperature over
a 60-min time period, and the duplex molecules were electrophoresed on
20% nondenaturing gels at 4 °C. Both native and denaturing gels
were analyzed by a Molecular Dynamics PhosphorImager.
UV and CD Analysis of 16-Mer Oligomers--
UV and CD spectra
were determined as described previously (27). DNA concentrations for
both analyses were first determined by measuring the absorbance at
260-nm wavelength at 80 °C using an Aviv 14DS-UV spectrophotometer
and integrating the known extinction coefficients for each DNA strand.
Equal amounts of complementary DNA were mixed and annealed as mentioned
above (0.5-ml total volume for UV, 1 ml for CD analysis). UV analysis
of single-stranded DNA and DNA duplexes were obtained at room
temperature on a Hewlett Packard 8452A diode array spectrophotometer.
The CD spectra were generated at room temperature using a Jasco J-600
spectropolarimeter. The raw CD data were converted to 
(M-1 cm-1) as described previously
(27).
Determination of B[a]P-DNA Adduct Distributions in Methylated
and Unmethylated Duplex DNA Oligomers--
The methylated and
unmethylated 16-mers shown in Fig. 6A were 5'-labeled with
[
-32P]ATP and T4 polynucleotide kinase. The labeled
strand was annealed to its complement by incubating both strands for 5 min at 85 °C in in 20 mM Tris-HCl, pH 7.5, 10 mM MgCl2, and 50 mM NaCl, followed by cooling to room temperature. The labeled duplex DNA was purified on
a 20% native polyacrylamide gel and desalted via Sep-Pak C-18 desalting columns (obtained from Waters, Inc., Milford, MA). Equal amounts of each duplex DNA (approximately 30 pmol) in a 50 mM NaPO4, pH 7.0, buffer solution were
incubated with 1 mM BPDE for 48 h in the dark at room
temperature. To denature the 32P-labeled strand from the
complement, a 25-fold excess of unlabeled 16-mer was added to each
reaction mixture, heated at 90 °C for 4 min, and then cooled to room
temperature. Small aliquots of the mixtures were then analyzed by 20%
native PAGE. The identities of the bands in the gel were determined by
comparing the mobilities of the bands in the reaction mixtures with
those of 32P-labeled and isomerically pure
B[a]P-DNA adducts of the same methylated and unmethylated
16-mer DNA molecules. The percentage of each isomer and the extent of
BPDE reactivity in the two reaction mixtures were obtained by
quantitation using a Molecular Dynamics PhosphorImager.
 |
RESULTS |
BPDE Modification of Duplex DNA--
A 51-nucleotide-long duplex
DNA oligonucleotide was prepared containing two CpG dinucleotides in
identical sequences contexts, one containing a 5-mC and one
unmethylated (Fig. 1B,
top strand). This strand was labeled at either
the 5'- or 3'-end with 32P (see "Experimental
Procedures"), equivalent amounts of each labeled duplex were mixed,
and this mixture was then reacted with a molar excess of BPDE. The
B[a]P-modified duplex was then cleaved with
DraI to produce two labeled fragments, a 28-mer, which
contained the methylated CpG, and a 24-mer, which was unmethylated. The modified products are the bands migrating slightly above the unmodified oligomers in the PAGE analysis shown in Fig.
2A. The extent of modification
was determined by PhosphorImager analysis, and these levels are shown
in Fig. 2B. From this analysis, it is clear that methylation
of the CpG sequence leads to enhanced BPDE reactivity with the
difference ranging from 3- to 4-fold over the range of BPDE
concentration. A similar enhancement in BPDE reactivity was also seen
if only the opposite strand contained a 5-mC.

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 1.
A, structures of the
anti-B[a]P-guanine adducts. B,
sequence of the DNA duplex used for determining the difference in
reactivity of BPDE toward methylated and unmethylated 5'-CpG-3'
sequences (indicated by the arrows). Following cleavage with
DraI, a methylated 28-mer and an unmethylated 24-mer are
generated.
|
|

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 2.
BPDE reactivity is enhanced at a
hemimethylated 5'-CpG-3' sequence. A, the
oligonucleotide shown in Fig. 1B was treated with BPDE,
cleaved with DraI, and then electrophoresed on a denaturing
polyacrylamide gel as described under "Experimental Procedures."
Identities of each species are as indicated. B, the level of
B[a]P modification at each site was determined by
analyzing the gel shown in A using a Molecular Dynamics
PhosphorImager. The relative percentage of modification at the
unmethylated site ( ) and methylated ( ) site is shown as a
function of the concentration of BPDE in the reaction relative to the
total number of guanines present in the oligonucleotide.
|
|
Since the vast majority of cellular CpG sites would be methylated in
both strands, an identical experiment was carried out where both
strands were methylated in the CpG sequence located on the 3'-side of
the 51-mer (Fig. 1B). As was found in the case of
hemimethylation, there was a clear enhancement of reactivity for the
methylated CpG sequence (Fig.
3A). Quantitation of the radioactivity present in the modified materials is shown in Fig. 3B, and the enhancement in this case ranged from 5- to
8-fold depending on the BPDE concentration. These enhanced levels of reactivity at methylated CpG sites are consistent with recently published data for in vitro reactivity of BPDE (22, 23).
When the reaction was carried out comparing the effect of methylation in the complementary strand in which both sites in the modified strand
were methylated, we found approximately a 2-fold enhancement (data not
shown), consistent with the differences shown in Figs. 2 and 3.

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 3.
Enhanced reactivity of BPDE at a fully
methylated 5'-CpG-3' sequence. A and B are
as shown in Fig. 2.
|
|
Structure Changes in Methylated CpG Sequences Modified with
BPDE--
To understand the molecular differences that lead to the
enhanced reactivity of methylated CpG sequences, we have attempted to
measure the effects of CpG methylation on the structures of B[a]P-modified oligonucleotides. For these studies, we
chose a 16-mer containing a single CpG site in a 5'-CGA-3' sequence
context (Fig. 4A).
Oligonucleotides of this length can be efficiently modified with BPDE,
and 16-mers containing each of the four B[a]P-dGuo isomers
are easily separable by HPLC. Native (Fig. 4) or denaturing (not shown)
PAGE analyses confirm that the isolated oligonucleotides are not
cross-contaminated with the other isomers or unmodified materials and,
as expected, run more slowly in the gel than the unmodified 16-mers
(17, 18, 27). The mobility differences in methylated DNA as opposed to
unmethylated DNA may be the result of a DNA structural distortion or a
conformational change caused by the presence of both a 5-mC and a
B[a]P-dGuo adduct isomer.

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 4.
PAGE analysis of
B[a]P-modified unmethylated and methylated
single-stranded 16-mers. A, the sequences of the
unmethylated and methylated 16-mers. B, the unmethylated and
methylated 16-mers were modified with BPDE, and the products containing
the four B[a]P isomers were purified by HPLC,
32P-labeled, and analyzed by native PAGE as described under
"Experimental Procedures."
|
|
Each of these oligonucleotides was 32P-labeled and
hybridized to the complementary unmethylated 16-mer, and the duplexes
were then analyzed by nondenaturing PAGE (Fig.
5). Under these gel conditions, there are
no noticeable differences in the migration rates of unmodified
methylated versus the unmodified unmethylated duplex DNAs
(Fig. 5, lanes c and d). This PAGE
analysis also shows, as expected, that the modified oligomers exhibit a
decrease in gel mobility compared with the unmodified DNA duplexes. The
(+)-trans-B[a]P-dGuo modified duplex, since it
is the most distorting B[a]P-dGuo adduct (12), gives rise
to a significant decrease in PAGE mobility as compared with the less
distorting minor adducts. Upon methylation, there is a significant
difference in the migration rate of the (+)-trans-B[a]P-dGuo-modified duplex (compare
lanes e and f), suggesting that there
is a significant structural change in this particular duplex that
results in a faster migration rate. Previous studies involving native
PAGE analyses of unmodified DNA duplexes have shown similar magnitude
mobility differences between duplex DNAs that are the result of DNA
structural alterations, most notably those of DNA curvature and bending
(28, 29). The methylation status of the remaining modified duplexes in
Fig. 5 (lanes g-l) has little or no effect on
the mobility of these samples. This suggests that although methylation
causes either no change or a small structural change for the minor
adduct isomers, a more significant structural change occurs in the
(+)-trans-B[a]P-dGuo-modified duplex that
results in the observed increased gel mobility. Interestingly, the
(+)-trans-B[a]P-dGuo adduct alone is positioned
on the outside of the helix pointing in the 5' direction, which is
toward the 5-mC location (12).

View larger version (42K):
[in this window]
[in a new window]
|
Fig. 5.
PAGE analysis of
B[a]P-modified unmethylated and methylated duplex
16-mers. A, the sequences of the unmethylated and
methylated duplex 16-mers. B, each of the
32P-labeled unmethylated and methylated 16-mers shown in
Fig. 4 was mixed with equal amounts of the complementary 16-mer and
analyzed by native PAGE as described under "Experimental
Procedures."
|
|
Effect of Methylation on the 3'-Side of the BPDE Adduct or in the
Complementary Strand--
To determine if the specific sequence or
position of the 5-mC relative to the modified guanine was important in
inducing the presumed structural change that was measured in the native
PAGE analysis (Fig. 5), an oligonucleotide was prepared in which there was a cytosine on both the 5'- and 3'-side of the guanine (Fig. 6A) along with versions of
this sequence where either the 5'- or 3'-C was methylated. These three
oligonucleotides were modified with BPDE, and the products containing
the four B[a]P-dGuo adduct isomers were isolated by HPLC.
Subsequent PAGE and analytical HPLC analysis indicated that these
materials were isomerically pure (not shown). Each of these
oligonucleotides were 32P-labeled and hybridized with the
complementary 16-mer. As was observed for the CGA sequence context, the
PAGE analysis of these duplexes indicated that the
(+)-trans-B[a]P-dGuo adduct containing the 5-mC
on the 5'-side gave the largest shift in mobility compared with the
unmethylated version (Fig. 6B, lanes e
and g). Thus, this effect appears to be independent of the
specific sequence context. In addition, a 5-mC on the 3'-side had
little if any effect on the mobility of any of the modified duplexes,
suggesting that the largest structural change appeared to be specific
for the combination of the (+)-trans-B[a]P-dGuo
adduct and the 5-mC on the 5'-side (Fig. 6B,
lanes f, i, l, and
o).

View larger version (48K):
[in this window]
[in a new window]
|
Fig. 6.
PAGE analysis showing the effect of a 5-mC
positioned 5' or 3' to the B[a]P adducts.
A, the sequences of the 5' or 3'-methylated duplex 16-mers.
B, the unmethylated 16-mer and two methylated 16-mers
(A) were modified with BPDE, and the products containing
each isomer were purified by HPLC. Each was then
32P-labeled, hybridized with equal amounts of complementary
16-mer, and analyzed by native PAGE as described under "Experimental
Procedures."
|
|
To determine the effect of a 5-mC in the complementary strand, duplexes
were prepared that were methylated opposite the B[a]P-dGuo adduct. Fig. 7A shows the PAGE
analysis where the modified strand contained a 5-mC positioned 5' to
the B[a]P-dGuo adduct. For each of the possible
combinations, a large mobility shift was observed only when the duplex
contained a 5-mC in the
(+)-trans-B[a]P-dGuo-modified strand (Fig.
7A, lanes g and i). None of
the other isomers nor the presence of only a 5-mC in the complementary
strand resulted in a significant mobility shift that could be observed
in the native PAGE analysis. Similarly, if the 5-mC was positioned 3' to the B[a]P-dGuo adducts and hybridized to a complement
containing a 5-mC opposite the adduct, very little if any shift in
mobility could be observed for any isomer (Fig. 7B).
Apparently, the combination of a
(+)-trans-B[a]P-dGuo adduct and a 5-mC on the
5'-side of the modified guanine is necessary to cause a significant
methylation-induced mobility shift.

View larger version (47K):
[in this window]
[in a new window]
|
Fig. 7.
PAGE analysis showing the effect of 5-mC in
the complement strand. The 16-mers shown in Fig. 6 were hybridized
to 16-mers that were either unmethylated or methylated on the C across
from the B[a]P-modified guanine. A, PAGE
analysis of the 16-mer containing a 5-mC in the strand 5' to the
modified guanine. B, PAGE analysis of the 16-mer containing
a 5-mC in the strand 3' to the modified guanine.
|
|
CD and UV Spectra of (+)-trans-B[a]P-dGuo DNA Duplexes--
The
minor groove positioning properties of the trans adducts and
the intercalation properties of the cis adducts have been determined by NMR (12, 13, 15, 16) and were reported earlier by
Geacintov and co-workers (30) using absorbance, fluorescence, and
linear and circular dichroism measurements. In these experiments, an
approximately 10-nm red-shifted absorbance for the B[a]P
absorption maxima for duplexes containing the cis adducts
was observed when compared with their single-stranded counterpart,
indicating that the pyrenyl ring was intercalated into the duplex. In
contrast, an approximately 10-nm blue shift was observed for the two
duplexes containing the trans adducts, indicating that the
adducts are outside the helix and exposed to solvent. To attempt to
characterize the apparent structural changes that are present in the
duplexes containing a 5-mC and a
(+)-trans-B[a]P-dGuo adduct, UV and CD spectra
were obtained for (+)-trans duplexes either methylated or
unmethylated at the 5'-C in the 5'-CGC-3' sequence context (Fig.
8). Neither the UV or CD spectra show any
significant differences that can be attributed to the presence of the
5-mC, suggesting that methylation is not causing the intercalation of
the (+)-trans adduct into the helix.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 8.
UV and CD analyses of the
(+)-trans B[a]P-containing 16-mer
duplexes. UV (A) and CD (B) spectra of
unmethylated (solid line) and methylated (broken
line) duplex 16-mers containing the (+)-trans
B[a]P-DNA adduct are shown.
|
|
Comparison of BPDE Reaction Products on Methylated and Unmethylated
DNA--
A prediction of the enhanced reactivity of the methylated
sites shown in Figs. 2 and 3 and the structural analysis shown in Figs.
5-7 is that there is a specific increase in the formation of the
(+)-trans-B[a]P isomer, since this isomer
contained within a methylated CpG sequence specifically shows a
conformational change relative to the identical unmethylated sequence.
In order to test this hypothesis, two duplex oligonucleotides
containing either a methylated or unmethylated CpG sequence were
reacted with BPDE, the strands were denatured, and the products were
analyzed by native PAGE (Fig. 9). This
gel was able to separate each of the four possible products from each
reaction as determined by comparison with authentic standards that were
separated and analyzed by HPLC. These data were analyzed in two ways
(Table I). First, the percentage of
modification of each isomer relative to the unreacted material was
determined, and it is evident from these data that not only does
methylation causes an enhanced reactivity with BPDE as was also shown
in Fig. 2 but also that this increase is specific for the formation of
the (+)-trans material. Second, when the relative amount of
each of the four isomers for each reaction was determined, it was clear
that in the case of the methylated sequence that this reaction has
become highly specific in the formation of the (+)-trans
isomer, producing less than 4% of the other three adducts, whereas in
the unmethylated sequence other isomers correspond to over 40% of the
total.

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 9.
Methylation results in increased amounts of
only the (+)-trans-B[a]P
adduct. The two duplex 32P-labeled oligonucleotides
shown were treated with equivalent amounts of BPDE, and the products
were analyzed by native PAGE as described under "Experimental
Procedures." The identity of each of the isomeric products was
determined by a comparison of the mobilities with those of authentic
B[a]P-modified 16-mers that had been purified and analyzed
by HPLC and PAGE.
|
|
View this table:
[in this window]
[in a new window]
|
Table I
BP-DNA isomer adduct yields after reaction of BPDE with methylated and
unmethylated duplex oligonucleotides
The gel shown in Fig. 9 was analyzed using a Molecular Dynamics
PhosphorImager to determine the amount of radioactivity present in each
band. The percentage of each isomer formed was the yield of each
product based on conversion of unmodified material to each specific
isomer. The values shown in parentheses correspond to the relative
amount of each isomer formed.
|
|
Modification of Duplex DNA with N-AAAF--
Recent studies have
indicated that other carcinogens, including N-AAAF, show
enhanced reactivity with methylated CpG sites in plasmid DNA (22, 23).
Because of the specificity that is observed in the present study for
the (+)-trans-B[a]P adducts, it seemed
surprising that other unrelated carcinogens would display similar
reactivities. To test this, the fully methylated duplex oligonucleotide
shown in Fig. 1B was reacted with N-AAAF and
cleaved with DraI, and the products were analyzed by PAGE
(Fig. 10). Unlike that which was
observed with BPDE modification, no enhanced reactivity was observed in
this case (Fig. 10B), suggesting that the results obtained
in the prior studies that showed enhanced reactivity for
N-AAAF may have resulted from differences in the reactivity of the UvrABC endonuclease that was used to measure the adduct formation.

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 10.
N-AAAF reactivity is not enhanced
at a fully methylated 5'-CpG-3' sequence. A, the
oligonucleotide shown in Fig. 1B was treated with
N-AAAF, cleaved with DraI, and then
electrophoresed on a denaturing polyacrylamide gel as described under
"Experimental Procedures." Identities of each species are as
indicated. B, the gel was analyzed as described in the
legend to Fig. 2. The relative percentage of modification at the
unmethylated site ( ) and the methylated ( ) site is shown as a
function of the concentration of N-AAAF in the reaction
relative to the total number of guanines present in the
oligonucleotide.
|
|
 |
DISCUSSION |
Cytosine methylation is known to play an important role in
numerous cellular processes, including cellular development, cell differentiation, genetic imprinting, X-chromosome inactivation, and
tumorigenesis (31-35). In addition, DNA methylation also appears to be
involved in mutagenesis, since transition mutation rates of cytosines
at CpG sites are 10-40 times higher compared with unmethylated sites
(36, 37). Because the majority of the mutations observed in human
cancers at these sites are C:G
T:A transitions (24, 38) and 5-mC is
known to deaminate 2-3-fold faster than unmethylated cytosine (39,
40), it has been suggested that most of these mutations arise by
endogenous cytosine deamination at methylated CpG sites. However, in
breast, liver, and lung tumors the percentage of C:G
A:T
transversions is often found to be equal to or higher than these
transition mutations (41). For example, in lung tumors there are three
CpG mutational hot spots at codons 157, 248, and 273 of the p53 gene
where the predominant type of mutation is this transversion. Recently,
it has been shown that these sites also appear to be preferential sites
for the reaction of a variety of carcinogens, including BPDE and
N-AAAF, an observation that may explain the enhanced levels
of C:G
A:T transversions that are observed in lung tumors (23, 24,
26, 38).
In the present study, it was found that CpG methylation caused a
substantial enhancement in the rate of reaction of
(±)-anti-BPDE with a purified duplex oligonucleotide
compared with reaction at an identical but unmethylated sequence. If
the site was methylated only in the strand that the BPDE was reacting,
about a 3-4-fold increase was observed, while a fully methylated CpG
sequence gave about an 5-8-fold enhancement over that occurring at an
unmethylated sequence. This latter value is consistent with the
enhancement observed for the reaction of BPDE with the p53 sequence
in vitro, which ranged from 2- to 10-fold, depending on the
sequence context of the CpG site (22, 23).
Cytosine methylation has been shown in the past to induce structural
changes in duplex DNA, and it may be these altered structures that are
responsible for the altered interactions with
benzo[a]pyrene derivatives. Thus, methylation has been
shown to slightly unwind the DNA helix (42), an effect that may result
from the minor distortion that has been observed in the DNA helix
caused by the positioning of the methylated GC base pair more toward
the minor groove (43). This latter effect also results in a concomitant decrease in the charge density in the major groove (44). Cytosine methylation has also been shown to cause a slight enhancement of the
curvature of "A-tract" DNA (45, 46), but in a random sequence only
small localized structural perturbations were seen (47, 48).
Interestingly, the CpG dinucleotide displays the strongest
base-stacking interactions and the greatest degree of minor groove
opening compared with each of the other DNA dinucleotides (49, 50).
Most relevant to the present study, it has been shown through
computational analyses (44) that cytosine methylation affords an
increased helical stability resulting in increased hydrophobicity and
molecular polarizability (51), and it may be these characteristics that
lead to the increased reactivity of BPDE at these sites. In agreement
with this prediction, the presence of multiple 5-methylcytosines in
duplex DNA were shown to result in greater levels of noncovalent
intercalation (52). Since BPDE is believed to first intercalate with
DNA prior to forming a covalent adduct, an increase in intercalation or
an altered structure may lead to the preferential modification seen in
this study. However, it should be noted that the effect observed for
DNA containing multiply methylated sites may not be a good predictor
for the effect of methylation at a single CpG site.
To determine if methylation affected the structure of BPDE-modified
DNA, a native gel analysis was used to measure conformational changes
in the duplex oligonucleotides. It has been shown in numerous studies
on DNA bending that differences in native gel mobility correlate with
structural changes in DNA (28, 29). We find here that the presence of a
5-mC on the 5'-side of a (+)-trans-B[a]P-dGuo adduct specifically induced a mobility shift that was not observed for
any of the other adducts, although the minor adduct did show a very
slight change in mobility. Methylation was found to increase the gel
mobility, suggesting that a more compact structure had formed, possibly
caused by an increase in intercalation of the adduct into the DNA
helix. However, the lack of a red shift in UV and CD analyses of DNA
duplexes containing a (+)-trans adduct, which would be
indicative of this enhanced intercalation, suggests that the
explanation may not be as simple as this.
These altered structures that were observed were not specific to a
single sequence, suggesting that the structural change was the result
of the presence of both a 5-mC and a
(+)-trans-B[a]P-dGuo adduct and not caused by a
sequence-mediated unique structure. Moreover, a 5-mC in the
complementary strand or 3' to the adduct position had little or no
effect on the gel mobility for any of the adduct stereoisomers. Taken
together, these data indicate that the structural change that is
observed is not simply the result of a simultaneous structural
alteration caused by the presence of a 5-mC and a B[a]P
adduct but instead indicate that there may be a unique conformation
that is induced by the presence of a 5-mC positioned 5' to a
(+)-trans-B[a]P-dGuo adduct.
The fact that the trans isomer specifically induces the
largest structural change in the methylated CpG sequence suggested that
it might be this adduct whose formation is increasing. This hypothesis
was tested by reacting two short duplex oligonucleotides that contained
either a methylated or unmethylated CpG sequence. The relative amounts
of each isomer were determined by native PAGE analysis and indicated
that this prediction was valid, since there was a specific increase in
only the (+)-trans material (Table I). Taken together with
the structural analysis, these data may provide an explanation for the
enhanced reactivity, possibly through a specific interaction between
the incoming BPDE and the 5-mC positioned 5' to the reacting guanine.
The likelihood that an altered structure exists for the methylated
(+)-trans isomer is supported by a recent study (53) that
used molecular modeling to show that methylation of CpG sequence
specifically increased the preference of only the (+)-trans
isomer to convert from an anti to syn conformation.
Methylation of CpG sequences has also been suggested to effect the
covalent binding of several other carcinogens that target guanine in
duplex DNA. Mitomycin C was the first of these to be shown to target
methylated CpG sequences, providing enhanced reactivity for both
alkylation and cross-linking (54). More recently, two related
cytotoxins, esperamicins A1 and C, were found to target CpG sequences
in highly methylated locations (55). Methylation of CpG sequences was
shown to enhance the levels of sunlight-induced cyclobutane pyrimidine
dimer formation (56) but inhibit the formation of 6-4 photoproducts
(57). Methylation has also resulted in decreased reactivity of both
N-methyl and ethyl-N-nitrosourea (58). From these
results, it is not clear if there are specific interactions, electronic
effects, or structures in the DNA that are responsible for these varied reactivities.
A recent study has suggested that benzo[g]chrysene diol
epoxide, aflatoxin B1, and N-AAAF all have enhanced
reactivity at methylated CpG sequences in vitro (23).
However, these results could also be explained by a differing
reactivity of the UvrABC endonuclease that is used in this analysis,
since the reactivity of this enzyme is known be influenced by the
structure of the damaged site (59). The results presented here show
that N-AAAF does not have enhanced reactivity at a fully
methylated CpG sequence (Fig. 10). Moreover, the fact that it is the
(+)-trans-B[a]P-dGuo isomer that is formed
almost exclusively at methylated CpG sites (Fig. 9 and Table I) and
that only this isomer shows a significant structural alteration in a
methylated sequence (Figs. 5-7) suggests that methylation is inducing
a structural change that participates in this reaction in a very
specific manner rather than through a global change or electronic
effect that targets many reactive species to these sites.
In conclusion, although most previous discussions of the role of 5-mC
in mutagenesis have suggested increased deamination rate in DNA, this
study has used a purified system to confirm other in vivo
and in vitro analyses that have shown that methylated CpG
sites react more readily with carcinogens. In addition, data has been
presented that provides support for the hypothesis that the mechanism
that causes this phenomenon is a structural change afforded by the
presence of the methylated cytosine 5' to the modified guanine. Future
studies will focus more closely on the nature of this structural change
and the effect of these different structures on DNA repair and
replication fidelity.
 |
FOOTNOTES |
*
This investigation was supported by Department of Health and
Human Services Public Health Service Grant CA 40605.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed. Tel.: 313-577-2584;
Fax: 313-577-8822; E-mail: ljr@chem.wayne.edu.
 |
ABBREVIATIONS |
The abbreviations used are:
B[a]P, benzo[a]pyrene;
BPDE, benzo[a]pyrene diol
epoxide;
(±)-anti-BPDE, ((±)-anti-r7,t8-dihydroxy-t9,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene;
B[a]P-dGuo, benzo[a]pyrene adduct at the N-2
position of guanine;
N-AAAF, N-acetoxy-N-acetyl-2-aminofluorene;
5-mC, 5-methylcytosine;
HPLC, high performance liquid chromatography;
PAGE, polyacrylamide gel electrophoresis.
 |
REFERENCES |
| 1.
|
Conney, A. H.
(1982)
Cancer Res.
42,
4875-4917[Free Full Text]
|
| 2.
|
Geacintov, N. E.,
Cosman, M.,
Hingerty, B. E.,
Amin, S.,
Broyde, S.,
and Patel, D. J.
(1997)
Chem. Res. Toxicol.
10,
111-146[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Yang, S. K.,
McCourt, D. W.,
Leutz, J. C.,
and Gelbolin, H. V.
(1977)
Science
196,
1199-1201[Abstract/Free Full Text]
|
| 4.
|
Yagi, H.,
Thakker, D. R.,
Hernandez, O.,
Koreeda, M.,
and Jerina, D. M.
(1977)
J. Am. Chem. Soc.
99,
1604-1611[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Yang, S. K.,
and Gelbolin, H. V.
(1976)
Biochem. Pharmacol.
25,
2221-2225[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Newbold, R. F.,
and Brookes, P.
(1976)
Nature
261,
52-54[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Wood, A. W.,
Chang, R. L.,
Levin, W.,
Yagi, H.,
Thakker, R. L.,
Jerina, D. M.,
and A. M, C.
(1977)
Biochem. Biophys. Res. Commun.
77,
1389-1395[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Buening, M. K.,
Wislocki, P. G.,
Levin, W.,
Yagi, H.,
Thakker, D. R.,
Akagi, H.,
Koreeda, M.,
Jerina, D. M.,
and Conney, A. H.
(1978)
Proc. Natl. Acad. Sci. U. S. A.
75,
5358-5361[Abstract/Free Full Text]
|
| 9.
|
Slaga, T. J.,
Bracken, W. J.,
Gleason, G.,
Levin, W.,
Yagi, H.,
Jerina, D. M.,
and Conney, A. H.
(1979)
Cancer Res.
39,
67-71[Abstract/Free Full Text]
|
| 10.
|
Weinstein, I. B.,
Jeffrey, A. M.,
Jennette, K. W.,
Blobstein, S. H.,
Harvey, R. G.,
Harris, C.,
Autrup, H.,
Kasai, H.,
and Nakanishi, K.
(1976)
Science
193,
592-595[Abstract/Free Full Text]
|
| 11.
|
Cheng, S. C.,
Hilton, B. D.,
Roman, J. M.,
and Dipple, A.
(1989)
Chem. Res. Toxicol.
2,
334-340[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Cosman, M.,
de los Santos, C.,
Fiala, R.,
Hingerty, B. E.,
Singh, S. B.,
Ibanez, V.,
Margulis, L. A.,
Live, D.,
Geacintov, N. E.,
Broyde, S.,
and Patel, D. J.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
1914-1918[Abstract/Free Full Text]
|
| 13.
|
de los Santos, C.,
Cosman, M.,
Hingerty, B. E.,
Ibanez, V.,
Margulis, L. A.,
Geacintov, N. E.,
Broyde, S.,
and Patel, D. J.
(1992)
Biochemistry
31,
5245-5252[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Mao, B.,
Li, B.,
Amin, S.,
Cosman, M.,
and Geacintov, N. E.
(1993)
Biochemistry
32,
11785-11793[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Cosman, M.,
de los Santos, C.,
Fiala, R.,
Hingerty, B. E.,
Ibanez, V.,
Luna, E.,
Harvey, R.,
Geacintov, N. E.,
Broyde, S.,
and Patel, D. J.
(1993)
Biochemistry
32,
4145-4155[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Cosman, M.,
Hingerty, B. E.,
Luneva, N.,
Amin, S.,
Geacintov, N. E.,
Broyde, S.,
and Patel, D. J.
(1996)
Biochemistry
35,
9850-9863[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Xu, R.,
Mao, B.,
Xu, J.,
Li, B.,
Birke, S.,
Swenberg, C. E.,
and Geacintov, N. E.
(1995)
Nucleic Acids Res.
23,
2314-2319[Abstract/Free Full Text]
|
| 18.
|
Liu, T.,
Xu, J.,
Tsao, H.,
Li, B.,
Xu, R.,
Yang, C.,
Amin, S.,
Moriya, M.,
and Geacintov, N. E.
(1996)
Chem. Res. Toxicol.
9,
255-261[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Xu, R.,
Mao, B.,
Amin, S.,
and Geacintov, N. E.
(1998)
Biochemistry
37,
769-778[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Tsao, H.,
Mao, B.,
Zhuang, P.,
Xu, R.,
Amin, S.,
and Geacintov, N. E.
(1998)
Biochemistry
37,
4993-5000[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Suh, M.,
Ariese, F.,
Small, G. J.,
Jankowiak, R.,
Liu, T. M.,
and Geacintov, N. E.
(1995)
Biophys. Chem.
56,
281-296[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Denissenko, M. F.,
Chen, J. X.,
Tang, M.,
and Pfeifer, G. P.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
3893-3898[Abstract/Free Full Text]
|
| 23.
|
Chen, J. X.,
Zheng, Y.,
West, M.,
and Tang, M.
(1998)
Cancer Res.
58,
2070-2075[Abstract/Free Full Text]
|
| 24.
|
Greenblatt, M. S.,
Bennett, W. P.,
Hollstein, M.,
and Harris, C. C.
(1994)
Cancer Res.
54,
4855-4878[Free Full Text]
|
| 25.
|
Tornaletti, S.,
and Pfeifer, G. P.
(1995)
Oncogene
10,
1493-1499[Medline]
[Order article via Infotrieve]
|
| 26.
|
Denissenko, M. F.,
Pao, A.,
Tang, M.-s.,
and Pfeifer, G. P.
(1996)
Science
274,
430-432[Abstract/Free Full Text]
|
| 27.
|
Arghavani, M. B.,
SantaLucia, J., Jr.,
and Romano, L. J.
(1998)
Biochemistry
37,
8575-8583[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Chen, J.-H.,
Seeman, N. C.,
and Kallenbach, N. R.
(1988)
Nucleic Acids Res.
16,
6803-6812[Abstract/Free Full Text]
|
| 29.
|
Nagaich, A. K.,
Bhattacharyya, D.,
Brahmachari, S. K.,
and Bansal, M.
(1994)
J. Biol. Chem.
269,
7824-7833[Abstract/Free Full Text]
|
| 30.
|
Geacintov, N. E.,
Cosman, M.,
Mao, B.,
Alfano, A.,
Ibanez, V.,
and Harvey, R. G.
(1991)
Carcinogenesis
12,
2099-2108[Abstract/Free Full Text]
|
| 31.
|
Doerfler, W.
(1983)
Annu. Rev. Biochem.
52,
93-124[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Li, E.,
Beard, C.,
and Jaenisch, R.
(1993)
Nature
366,
362-365[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Riggs, A. D.,
and Pfeifer, G. P.
(1992)
Trends Genet.
8,
169-174[Medline]
[Order article via Infotrieve]
|
| 34.
|
Jones, P. A.,
Rideout, W. M., III,
Shen, J. C.,
Spruck, C. H.,
and Tsai, Y. C.
(1992)
BioEssays
14,
33-36[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Laird, P. W.,
and Jaenisch, R.
(1996)
Annu. Rev. Genet.
30,
441-464[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Cooper, D. N.,
and Youssoufian, M.
(1988)
Human Genet.
78,
151-155[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Koeberl, D. D.,
Botteman, C. D. K.,
Ketterling, R. P.,
Bridge, P. J.,
Lillicrap, D. P.,
and Sommer, S. S.
(1990)
Am. J. Hum. Genet.
47,
202-217[Medline]
[Order article via Infotrieve]
|
| 38.
|
Hollstein, M.,
Rice, K.,
Greenblatt, M. S.,
Soussi, T.,
Fuchs, R.,
Sorlie, T.,
Hovig, E.,
Smith-Sorensen, B.,
Montesano, R.,
and Harris, C. C.
(1994)
Nucleic Acids Res.
22,
3551-3555
|
| 39.
|
Frederico, L. A.,
Kunkel, T. A.,
and Shaw, B. R.
(1990)
Biochemistry
29,
2532-2537[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Shen, J.-C.,
Rideout, W. M., III,
and Jones, P. A.
(1994)
Nucleic Acids Res.
22,
972-976[Abstract/Free Full Text]
|
| 41.
|
Levine, A. J.,
Wu, M. C.,
Chang, A.,
Silver, A.,
Attiyeh, E. F.,
Lin, J.,
and Epstein, C. B.
(1995)
Ann. N. Y. Acad. Sci.
768,
111-128[Medline]
[Order article via Infotrieve]
|
| 42.
|
Zacharias, W.,
O'Connor, T. R.,
and Larson, J. E.
(1988)
Biochemistry
27,
2970-2978[CrossRef][Medline]
[Order article via Infotrieve]
|
| 43.
|
Heinemann, U.,
and Hahn, M.
(1992)
J. Biol. Chem.
267,
7332-7341[Abstract/Free Full Text]
|
| 44.
|
Hausheer, F. H.,
Rao, S. N.,
Gamcsik, M. P.,
Kollman, P. A.,
Colvin, O. M.,
Saxe, J. D.,
Nelkin, B. D.,
McLennan, I. J.,
Barnett, G.,
and Baylin, S. B.
(1989)
Carcinogenesis
10,
1131-1137[Abstract/Free Full Text]
|
| 45.
|
Hodges-Garcia, Y.,
and Hagerman, P. J.
(1992)
Biochemistry
31,
7595-7599[CrossRef][Medline]
[Order article via Infotrieve]
|
| 46.
|
Hagerman, P. J.
(1990)
Biochemistry
29,
1980-1983[CrossRef][Medline]
[Order article via Infotrieve]
|
| 47.
|
Hodges-Garcia, Y.,
and Hagerman, P. J.
(1995)
J. Biol. Chem.
270,
197-201[Abstract/Free Full Text]
|
| 48.
|
Diekmann, S.
(1987)
EMBO J.
6,
4213-4217[Medline]
[Order article via Infotrieve]
|
| 49.
|
Saenger, W.
(1984)
in
Principles of Nucleic Acid Structure
(Cantor, C., ed)
, pp. 116-140, Springer-Verlag New York Inc., New York
|
| 50.
|
Ulyanov, N. B.,
and Zhurkin, V. B.
(1984)
J. Biomol. Struct. Dyn.
2,
361-385[Medline]
[Order article via Infotrieve]
|
| 51.
|
Sowers, L. C.,
Shaw, B. R.,
and Sedwick, W. D.
(1987)
Biochem. Biophys. Res. Commun.
148,
790-794[CrossRef][Medline]
[Order article via Infotrieve]
|
| 52.
|
Geacintov, N. E.,
Shahbaz, M.,
Ibanez, V.,
Moussaoui, K.,
and Harvey, R. G.
(1988)
Biochemistry
27,
8380-8387[CrossRef][Medline]
[Order article via Infotrieve]
|
| 53.
|
Perlow, R. A.,
Schor, J. A.,
Hingerty, B. E.,
Geacintov, N. E.,
Scicchitano, D. A.,
and Broyde, S.
(1999)
Proc. Am. Assoc. Cancer Res.
40,
506
|
| 54.
|
Johnson, W. S.,
He, Q.-Y.,
and Tomasz, M.
(1995)
Bioorg. Med. Chem.
3,
851-860[CrossRef][Medline]
[Order article via Infotrieve]
|
| 55.
|
Mathur, P.,
Xu, J.,
and Dedon, P. C.
(1997)
Biochemistry
36,
14868-14873[CrossRef][Medline]
[Order article via Infotrieve]
|
| 56.
|
Tommasi, S.,
Denissenko, M. F.,
and Pfeifer, G. P.
(1997)
Cancer Res.
57,
4727-4730[Abstract/Free Full Text]
|
| 57.
|
Pfeifer, G. P.,
Drouin, R.,
Riggs, A. D.,
and Holmquist, G. P.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
1374-1378[Abstract/Free Full Text]
|
| 58.
|
Mathison, B. H.,
Said, B.,
and Shank, R. C.
(1993)
Carcinogenesis
14,
323-327[Abstract/Free Full Text]
|
| 59.
|
Mekhovich, O.,
Tang, M.,
and Romano, L. J.
(1998)
Biochemistry
37,
571-579[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles: